Sees Q3 revenue up 17%-19%. The company said, “The company estimates net sales growth for the third quarter of 2025, versus the prior year period, to be in a range of approximately 17 to 19 percent on a reported basis, and 12 to 14 percent on an organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.44 to $0.46 and estimates adjusted EPS, excluding certain charges, of $0.70 to $0.72.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Notable companies reporting before tomorrow’s open
- BSX Upcoming Earnings Report: What to Expect?
- Boston Scientific: Strong Growth Potential and Positive Outlook Justify Buy Rating
- Boston Scientific’s Sustained Growth and Margin Expansion Justify Buy Rating
- LAAX device study pause a positive update for Boston Scientific, says BofA